Publications by authors named "Tatiana D'Angelo"

Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer is a major global health issue, often linked to genetic mutations in the BRCA1 and BRCA2 genes, particularly in patients with Triple Negative Breast Cancer (TNBC) who are at high risk.
  • The study focuses on a specific variant (BRCA1 c.5057A>C, p.(His1686Pro)) classified as a Variant of Unknown Significance (VUS) in a TNBC patient, highlighting the importance of analyzing various data sources to assess its impact on cancer risk.
  • The findings suggest that by combining clinical history and molecular evidence, a more accurate classification of VUS can enhance personalized treatment strategies and improve outcomes for breast cancer patients.
View Article and Find Full Text PDF

The prevention of chemotherapy-induced alopecia still represents an urgent need for every day clinical practice. In this regard, this prospective single-center study included breast cancer (BC) patients who underwent a scalp cooling device (Dignicap) during (neo)adjuvant chemotherapy with the aim to evaluate the efficacy and safety of this device in preventing alopecia. One hundred and seventy-eight patients (median age 43 years) were enrolled.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is characterized by earlier recurrence and shorter survival compared with other types of breast cancer. Moreover, approximately 15 to 25% of all TNBC patients harbor germline BRCA (gBRCA) 1/2 mutations, which confer a more aggressive phenotype. However, TNBC seems to be particularly sensitive to chemotherapy, the so-called 'triple negative paradox'.

View Article and Find Full Text PDF

Breast cancer is the leading cause of death in the female population and despite significant efforts made in diagnostic approaches and treatment strategies adopted for advanced breast cancer, the disease still remains incurable. Therefore, development of more effective systemic treatments constitutes a crucial need. Recently, several clinical trials were performed to find innovative predictive biomarkers and to improve the outcome of metastatic breast cancer through innovative therapeutic algorithms.

View Article and Find Full Text PDF

: Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient.

View Article and Find Full Text PDF